{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for icosapent root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
INN:sacituzumab tirumotecan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab corixetan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegloxenatide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegloprastide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04699630: Phase 2 Interventional Active, not recruiting Metastatic Breast Cancer
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03255070: Phase 1 Interventional Completed Breast Neoplasms
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03595059: Phase 1 Interventional Active, not recruiting Advanced Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pivekimab sunirine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03507452: Phase 1 Interventional Completed Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04189614: Phase 1 Interventional Active, not recruiting Cancer
(2020)
Source URL:
Class:
PROTEIN
